- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.03. | Leerink cuts OnKure stock price target on strategic shift | 1 | Investing.com | ||
| 30.03. | OnKure Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.03. | Oppenheimer reiterates OnKure stock rating on pipeline shift | 1 | Investing.com | ||
| 27.03. | OnKure Therapeutics prices $150M oversubscribed private placement | 1 | Seeking Alpha | ||
| ONKURE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 27.03. | OnKure raises $150M to advance breast cancer programs | 1 | Investing.com | ||
| 12.03. | OnKure Therapeutics GAAP EPS of -$0.09 | 2 | Seeking Alpha | ||
| 12.03. | OnKure Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 12.03. | OnKure Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 12.03. | OnKure Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.11.25 | OnKure Therapeutics GAAP EPS of -$1.09 | 2 | Seeking Alpha | ||
| 06.11.25 | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update | 206 | GlobeNewswire (Europe) | -- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients... ► Artikel lesen | |
| 06.11.25 | OnKure Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.05.25 | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | 354 | GlobeNewswire (Europe) | -- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data -- Expansion of the Company's... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 23,100 | -0,58 % | JPMORGAN stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Pfizer mit einem Kursziel von 30 US-Dollar auf "Neutral" belassen. Chris Schott sieht für die Ziele des Pharmaherstellers Luft... ► Artikel lesen | |
| SANOFI | 80,64 | +1,36 % | JPMORGAN stuft SANOFI auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Sanofi mit einem Kursziel von 95 Euro auf "Neutral" belassen. Analyst Richard Vosser wertet die Ergebnisse der Phase-II-Studien... ► Artikel lesen | |
| INNOCAN PHARMA | 3,910 | +0,51 % | InnoCan Pharma im Höhenflug: Warum Insider bereits massiv kaufen - Was Sie jetzt noch wissen müssen | ||
| ASSEMBLY BIOSCIENCES | 25,000 | +0,60 % | Assembly Biosciences vor ESCMID-Auftritt: Ab ins Rampenlicht | Mein Biotech-Favorit Assembly Biosciences rückt zunehmend in den Fokus der internationalen Wissenschafts- und Investorengemeinde. Das Unternehmen kündigte an, mehrere Datensätze aus jüngsten Proof-of-Concept-Studien... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 69,58 | +1,73 % | Nektar Therapeutics: Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting | Rezpegaldesleukin demonstrates statistically significant improvement in mean percent EASI improvement across both moderate and severe atopic dermatitis patients
Rezpegaldesleukin... ► Artikel lesen | |
| UNITED THERAPEUTICS | 494,30 | +1,92 % | Raymond James stuft United Therapeutics mit "Outperform" ein - Kursziel 700 Dollar | ||
| JAGUAR HEALTH | 0,389 | -0,23 % | Jaguar Health, Inc.: Artificial Intelligence Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure Programs | Global Market for Short Bowel Syndrome, Including Intestinal Failure (IF), Estimated to Reach $8.0 Billion by 20331AI data mining of real world clinical and symptom manifestation is beneficial in the... ► Artikel lesen | |
| ROYALTY PHARMA | 41,220 | +0,06 % | Royalty Pharma plc - 8-K, Current Report | ||
| BRIDGEBIO PHARMA | 66,00 | -0,35 % | RBC Capital startet Coverage für BridgeBio Pharma mit "Outperform" und Kursziel 100 US-Dollar | ||
| CORBUS PHARMACEUTICALS | 8,800 | +1,38 % | Corbus completes enrollment in obesity drug trial | ||
| SOLIGENIX | 1,145 | -0,87 % | RedChip Companies, Inc.: BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | ORLANDO, FL / ACCESS Newswire / April 10, 2026 / RedChip Companies will air interviews with BIO-key International, Inc. (Nasdaq:BKYI), 20/20 Biolabs, Inc. (Nasdaq:AIDX), Society Pass Inc. (Nasdaq:SOPA)... ► Artikel lesen | |
| KALA BIO | 0,194 | +3,20 % | KALA BIO, Inc.: Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities | TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio Inc. (NASDAQ: KALA), a clinical-stage biopharmaceutical company at the forefront of artificial intelligence and cell and gene therapy innovation... ► Artikel lesen | |
| EVOLUS | 3,776 | +2,41 % | Evolus, Inc. - 8-K, Current Report | ||
| ACLARIS THERAPEUTICS | 3,394 | +2,23 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis | - Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| NEUROGENE | 16,700 | +1,83 % | Morning Market Movers: Neurogene, Duolingo, Xponential Fitness, Emergent BioSolutions See Big Swings | WASHINGTON (dpa-AFX) - At 6:22 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |
ONKURE THERAPEUTICS INC gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von +0,165 (+3,71 %) liegt der Kurs bei 4,615 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONKURE THERAPEUTICS INC finden Sie auf Wallstreet Online.